This week, Federal Judge Kacsmaryk of Northern District of Texas concluded that the FDA erred in 2000 when it granted Accelerated Approval to mifepristone as an agent to facilitate a medical abortion.
As is true in so many fields, medicine and biomedical research have experienced a huge transition over recent decades from self-sufficiency to productive interdependence.
Russia’s invasion a year ago has exacerbated the problems that afflicted Ukraine’s health care system, creating a new threat to the lives of patients struggling with cancer.
In 1991, Ukraine started to transform its healthcare system, and these changes continue to this day.
Shortly, I will step aside as director of the University of Iowa Holden Comprehensive Cancer Center, a role I have served in since 1998, i.e. a term roughly bookended by Y2K and COVID.
Cancer specialists like me, whether they are medical, surgical, or radiation oncologists spend our lives treating life threatening disease. We generally have a serious and professional demeanor reflective of the world that we choose to inhabit and the circumstances facing our patients that entrust us with their care.
One city is famous for its cheesesteaks. The other—a known hotspot for some of the country’s best barbecue.
Ten miles south of my job at the Chao Family Comprehensive Cancer Center, an Asian American elder opened fire and killed one person at the Taiwanese Presbyterian Church in Laguna Woods, CA.
As members of the 118th Congress returned to Washington this week, everyone is focused on raising the nation’s debt limit, especially following Treasury Secretary Jane Yellen’s announcement that her agency would begin taking extraordinary measures to prevent the government from triggering a default.
Over and over again, I’ve seen the same missteps, clumsy excuses, and faulty logic during sponsor presentations to the FDA Oncologic Drugs Advisory Committee, repeated as if part of a tragic, regulatory update to the movie Groundhog Day.
